The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Anita KumarDuring the #ASCO22 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)?
What is on the horizon for the frontline treatment of MCL?
Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in the relapsed/refractory setting; results of studies, such as SHINE, have explored this. Finally, Kumar discusses other therapeutic options and outlines adverse events and efficacy seen in the current OASIS phase III trial.